uniQure price target raised to $31 from $16 at Chardan

Chardan raised the firm’s price target on uniQure (QURE) to $31 from $16 and keeps a Buy rating on the shares. The FDA’s CBER Director, Dr. Vinay Prasad, will reportedly leave the agency at the end of April following a controversial tenure marked by several reversals and disputes over regulatory decisions in rare disease treatments, the analyst tells investors in a research note. His departure follows public criticism related to the FDA’s requirement that uniQure conduct a new sham surgery-controlled trial for its Huntington’s disease therapy AMT-130, the firm adds.